Literature DB >> 14630763

Joining the DoTS: new approach to classifying adverse drug reactions.

J K Aronson1, R E Ferner.   

Abstract

Mesh：

Year:  2003        PMID： 14630763      PMCID： PMC274067          DOI： 10.1136/bmj.327.7425.1222

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  22 in total

1.  Forbidden fruit.

Authors:  J K Aronson
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

Review 2.  Cephalosporin allergy.

Authors:  P S Kelkar; J T Li
Journal:  N Engl J Med       Date:  2001-09-13       Impact factor: 91.245

3.  Clinical pharmacology. Adverse reactions to drugs.

Authors:  M D Rawlins
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-21

4.  Serious adverse events of mefloquine in relation to blood level and gender.

Authors:  E Schwartz; I Potasman; M Rotenberg; S Almog; S Sadetzki
Journal:  Am J Trop Med Hyg       Date:  2001-09       Impact factor: 2.345

5.  Natriuretic efficiency of frusemide as a consequence of drug input rate.

Authors:  M Wakelkamp; G Alván; G Paintaud
Journal:  Br J Clin Pharmacol       Date:  1997-05       Impact factor: 4.335

6.  Quantitative relationships between sensitizing dose of DNCB and reactivity in normal subjects.

Authors:  P S Friedmann; C Moss; S Shuster; J M Simpson
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

7.  Jaundice after repeated exposure to halothane: an analysis of Reports to the Committee on Safety of Medicines.

Authors:  W H Inman; W W Mushin
Journal:  Br Med J       Date:  1974-01-05

8.  The ampicillin rash as a diagnostic and management problem: case reports and literature review.

Authors:  J P Geyman; S Erickson
Journal:  J Fam Pract       Date:  1978-09       Impact factor: 0.493

9.  Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs.

Authors:  D J Greenblatt; M Divoll; J S Harmatz; D S MacLaughlin; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

10.  Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.

Authors:  J R Batchelor; K I Welsh; R M Tinoco; C T Dollery; G R Hughes; R Bernstein; P Ryan; P F Naish; G M Aber; R F Bing; G I Russell
Journal:  Lancet       Date:  1980-05-24       Impact factor: 79.321
View more
  71 in total

Review 1.  Detection, verification, and quantification of adverse drug reactions.

Authors:  Bruno H Ch Stricker; Bruce M Psaty
Journal:  BMJ       Date:  2004-07-03

2.  Assessing the benefit-harm balance at the bedside.

Authors:  Yoon Kong Loke
Journal:  BMJ       Date:  2004-07-03

3.  Monitoring drug therapy.

Authors:  Thierry Buclin; Verena Gotta; Aline Fuchs; Nicolas Widmer; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

4.  Pharmacovigilance.

Authors:  I Ralph Edwards
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

Review 5.  Developing drug prototypes: pharmacology replaces safety and tolerability?

Authors:  Adam F Cohen
Journal:  Nat Rev Drug Discov       Date:  2010-09-17       Impact factor: 84.694

6.  Recurrence of adverse drug reactions following inappropriate re-prescription: better documentation, availability of information and monitoring are needed.

Authors:  Carolien M J van der Linden; Paul A F Jansen; Rob J van Marum; René J E Grouls; Erik H M Korsten; Antoine C G Egberts
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

7.  An algorithm for integrating contraindications into electronic prescribing decision support.

Authors:  Robin E Ferner; Jamie J Coleman
Journal:  Drug Saf       Date:  2010-12-01       Impact factor: 5.606

8.  Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

9.  A manifesto for clinical pharmacology from principles to practice.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 10.  Monitoring in chronic disease: a rational approach.

Authors:  Paul Glasziou; Les Irwig; David Mant
Journal:  BMJ       Date:  2005-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.